Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the Elderly
07 Junio 2024 - 7:18PM
Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology
company, is pleased to announce that the RESILIENCE Study, a
clinical trial evaluating a new immunomodulator designed to
strengthen natural immunity among seniors aged 65 or older, is
enrolling participants in the study.
Why are we conducting this study?As we age, our
immune function declines, leaving us susceptible to the development
of diseases such as cancer, chronic inflammatory diseases, and
infections, and decline in health. The RESILIENCE study is
assessing the effectiveness of a novel immunomodulator designed to
boost immune function in the elderly and reverse the natural
decline in immune function that occurs with aging. The Principal
Investigator of the study is Dr. Ted Steiner, Chief Medical Officer
of Qu Biologics, and Professor of Medicine and Head of Infectious
Diseases at the University of British Columbia.
Study collaboratorsThe study is a collaboration
between Qu Biologics, the University of British Columbia, Vancouver
Coastal Health Research Institute, and Providence Health Care. The
study has received funding from the Government of Canada through
NRC-IRAP (National Research Council of Canada - Industrial Research
Assistance Program).
Dr. Hal Gunn, CEO of Qu Biologics, states, "There aren’t any
current therapies that improve innate immune function in the
elderly. If this study is successful in demonstrating that this new
immunomodulator can reverse the decline in innate immunity in the
elderly, it has important implications for human health and the
extension of healthy longevity”.
More than 110 people have been treated with the new
immunomodulator, with a good safety profile to date. Derived from
inactivated bacteria, the immunomodulator is designed to ‘train’
innate immunity to improve immune system resilience. Dr. Shirin
Kalyan, Qu’s VP Scientific Innovation, states, “Clinical studies
allow us to test the safety and effectiveness of new treatment
approaches. Qu is keenly interested in the ways we may be able to
improve immune function to restore or optimize health and healthy
longevity. By investigating innovative immunomodulatory therapies,
we hope to learn how to enhance senior’s resilience against
diseases and infections, ultimately improving their overall health
and quality of life."
Adults aged 65 or older living in the Greater Vancouver Area are
invited to learn more about participating in this study. For more
information about this clinical trial, please contact
1-877-223-8637, email info@isstudy.ca, or head to our study
website, here.
Media Contact:Hal Gunn, MD CEO, Qu
Biologics Inc. Phone: 604.734.1450 Email:
media@qubiologics.com
About Qu BiologicsQu Biologics is a clinical
stage biotechnology company developing Site Specific
Immunomodulators (SSI), a novel class of immunotherapies designed
to restore innate immune function in targeted organs to reverse the
immune dysregulation underlying many important diseases including
cancer, chronic inflammatory diseases, metabolic disease, and
infection. Qu Biologics has completed four Phase 2 studies in lung
cancer, Crohn’s disease, and ulcerative colitis. Two additional
Phase 2 randomized placebo-controlled studies, in late-stage colon
cancer and immunosenescence, are underway.
Backed by a prestigious group of scientific advisors and board
members, Qu Biologics is led by a management team that includes
co-founder and CEO Dr. Hal Gunn, a physician and expert on the
body’s immune response to chronic disease; Chief Medical Officer -
Oncology Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency
and a distinguished clinician, scientist and leader in cancer
control in Canada and internationally; and Chief Medical Officer –
Infectious Disease Dr. Ted Steiner, a clinician-scientist
specializing in immune responses to infections and Head of the UBC
Division of Infectious Diseases. For more information, please visit
www.qubiologics.com.
Qu Biologics Inc. cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Qu Biologics’ forward-looking statements due to the
risks and uncertainties inherent in Qu Biologics’ business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Qu Biologics
does not assume any obligation to update any forward-looking
statements except as required by law.
For more information regarding this press release, contact:
Hal Gunn, MD
CEO
Qu Biologics Inc.
Phone: 604.734.1450
Email: media@qubiologics.com